The Mechanism of Action of Palbociclib

February 7, 2014
Gunter von Minckwitz, MD, PhD

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, explains the mechanism of palbociclib, a novel oral selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, explains the mechanism of palbociclib, a novel oral selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6.

Clinical Pearls:

  • By inhibiting CDK 4 and 6, the agent prevents DNA synthesis by prohibiting progression from G1 to S phase of the cell cycle
  • The agent also inhibits phosphorylation of the RB protein
  • Palbociclib prohibits cell proliferation